ArticleThe World Allergy Organization journal2025
Anaphylaxis and pregnancy: Epidemiology, elicitors, and recurrences.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anaphylaxis during pregnancy implies a risk to both mothers and newborns. However, limited data are available. Therefore, our aim is to explore patterns of hospital admissions diagnosed with anaphylaxis in pregnant women in France from 2012 to 2021, using a national hospital billing database and to evaluate potential determinants, trends and recurrences. Methods: Descriptive study using data from the French Program for the Medicalization of Information Systems, from 2012 to 2021. We included all patients hospitalized for anaphylaxis using International Classification of Diseases (ICD)-10 codes listed as a primary diagnosis. Two groups of patients were included: pregnant (PW) and non-pregnant women (NPW), adjusted by age. Severe anaphylaxis (SA) was defined based on the need of admissions in intensive care units. Sankey graphics were employed to visualize data related to recurrences. Results: During a nine-year study period, 37,962 female patients had 42,399 admissions due to anaphylaxis for all causes. We evaluated data from 734 admissions for anaphylaxis experienced by 653 PW. In both groups 65% of cases were unspecified anaphylaxis, with high number of recurrences. PW experienced higher proportion of SA (8.7%, 95%CI [6.8%, 11.1%]) and recurrences (1.51, 95%CI [1.3, 1,7]), compared with NPW. Most of SA in PW was triggered by drugs (23%, 95%CI [22.3%, 23.6%]). Different from NPW, no seasonal trend was observed in the PW group. From all 670 PW who experienced non-SA, 0.33% (95% CI 0.09-1.2) evolved with SA, and 0.92% (95% CI 0.42-1.99) were admitted for different etiologies in forthcoming admissions. Conclusion: Beyond providing a snapshot of characteristics of anaphylaxis during pregnancy in France, we were able to explore trends and recurrence of anaphylaxis in this population. Although further research is needed in the field, we strongly believe that the data presented contributed as a starting point of public health advancements to ensure quality of care of patients suffering from anaphylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.